New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|February 6, 2015
PARP Inhibitors for Ovarian Cancer
Author(s)Donna McNamara, MD
Donna McNamara, MD, discusses PARP inhibitors for the treatment of ovarian cancer.
Advertisement
Clinical Pearls
Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, discusses PARP inhibitors for the treatment of ovarian cancer.
- In breast cancer, maintenance drugs exist to keep patients in remission following chemotherapy. There remains a need for such agents in ovarian cancer.
- Though only 10-15% of patients harbor a BRCA1/2 mutation, they may see benefit from treatment with a PARP inhibitor.
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
4
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
5